Close menu

August 18th, 2021 | 10:43 CEST

Bayer, Cardiol Therapeutics, CureVac: The Champions League of Bio-Pharma!

  • Biotechnology
Photo credits:

Biopharmaceutics is the first port of call in the fight against a wide range of diseases. It studies the relationship between drugs and excipients' chemical and physical properties and their form of administration in a living organism. Biological effectiveness results from the entry of the drug into the diseased organism, its distribution in tissues, and the chemical reaction called metabolism. When dealing with recent pandemics, good advice is expensive, and research into pharmaceuticals costs billions. When an active ingredient is found and registered, the patent clock starts ticking for the inventor. As a result, the hope of the biopharmaceutical company is to remain the sole provider in their healing segment for as long as possible.

time to read: 5 minutes | Author: André Will-Laudien
ISIN: BAYER AG NA O.N. | DE000BAY0017 , CARDIOL THERAPEUTICS | CA14161Y2006 , CUREVAC N.V. O.N. | NL0015436031

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    Bayer - The Hardeman case ends up before the Supreme Court after all
    Issues in bio-pharma do not always revolve around research and product launches. Bayer went straight into the clutches of the US judiciary after the Monsanto acquisition in 2018. From a German perspective, it should have been known better after Dieselgate that US attorneys readily target bulging corporate coffers. After VW, Bayer is now also feeling the effects of this playground for lawyers.

    The purchase price for Monsanto was USD 66 billion, making it the largest takeover by a German company abroad to date. Although this makes Bayer the world's number one in the agrochemicals business, it also means it takes on the inherited debts from the glyphosate affair. Bayer has already set aside around USD 11 billion for a settlement package to resolve US lawsuits. Some 96,000 cases have already been finally settled, but more will follow.

    In the Edwin Hardeman case, Bayer counts on a supreme court decision in the billion-dollar legal dispute. The DAX-listed Company filed a petition for review with the Supreme Court at the beginning of the week. Specifically, this case is about a cancer brought about in connection with regular contact with glyphosate. A smaller US court has already awarded the plaintiff a total of just over USD 25 million in damages. Should the highest US court accept the case for decision and judge in the interests of Bayer, this would have a high signal effect for future lawsuits and their chances of success against Bayer.

    Glyphosate has now been an issue since mid-2018. Bayer shares are now worth about 30% less than the Monsanto acquisition cost at the time. Again, an example (similar to Daimler-Chrysler) of failed German entries into the US market. The M&A learning curve is probably still at the beginning; it is the biggest value destruction in the Company's history for Bayer shareholders. But, one should follow the Supreme Court's actions closely now because Bayer has already made substantial provisions in recent years. So, balance sheet explosives are lying dormant here!

    Cardiol Therapeutics - There is much more to it than that
    Cardiol Therapeutics Inc. is a biotechnology company focused on the discovery and clinical development of innovative anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). The Company's lead product, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is currently being evaluated in a Phase II/III outcome study in hospitalized patients who tested positive for the COVID-19 virus.

    Research is well advanced and this potential pivotal study could demonstrate the efficacy and safety of CardiolRx as a cardioprotective therapeutic to reduce mortality. The analysis of major cardiovascular events in COVID-19 patients associated with prior cardiovascular disease is of interest in this regard. What are the risk factors for HKE, and what is the impact of CardiolRx on important markers of inflammatory heart disease? Without exaggeration, perhaps the solution to many coronary diseases of our time lies here. After all, this indication remains the most common cause of sudden cardiac death in people under 35 years of age.

    Cardiol Therapeutics has now also been listed on the NASDAQ since August 10. It is a mark of distinction, as not every biotech company makes this leap. Cardiol thus pushes open the door to further sources of financing, as many institutional investors require higher market segments to be allowed to invest at all. Cardiol can now raise growth capital much more easily.

    Cardiol Therapeutics was able to come up with a surprising price jump yesterday. Early in the morning, EUR 2.86 was called. The calculated price at the previous day's close in Canada would have been only EUR 2.10. The reason could be the remaining euphoria about the NASDAQ listing and a rating confirmation by GBC Research, which calculated a price target of CAD 17.49 in its update to the latest buy study. The current price is hovering around CAD 3.40 - that would be a mathematical fivefold increase. Urgently take a few pieces into your portfolio.

    CureVac - Still a lot in the quiver?
    After an extended rally by BioNTech and Moderna, many wonder what is going on with CureVac. The approval applications for the first vaccine, "CVnCoV," failed in the EU due to an efficacy of only 47%. As a result, the price of CureVac has plummeted by almost 60% since June. In the meantime, however, solid chart support has formed in the range of EUR 45 to 50. Can a comeback now be expected? We take a look at the fundamental development.

    CureVac was considered an mRNA pioneer at the beginning of the pandemic. The manufacturer from Tübingen, however, recently flopped with its vaccine against Covid-19. On closer inspection, the problems were already apparent at the start: While numerous competitors had long since brought their vaccines to market, CureVac was still collecting data. Neither the decline in the incidence of infection nor the occurrence of mutations could be blamed for this. It was due to the technology, which is the problem at CureVac: Unlike BioNTech and Moderna, CureVac did not replace uridine with pseudouridine, which, according to studies, prevents the degradation of mRNA and minimizes immune reactions. This error is now said to have been corrected.

    A new vaccine candidate can already achieve better results: "CV2CoV" is being developed with the major partner GlaxoSmithKline (GSK). A first preclinical study has shown strongly improved immune responses. Currently, the vaccine is still being tested in cynomolgus monkeys. There is at least hope that CureVac has learned and will only go to market again with results once high validity has been achieved.

    Hope is flaring up again for CureVac. The share price is rising - most recently 10% in just 3 days. If a better 2nd generation vaccine is indeed invented, the way is paved for significantly higher share prices. All in all, we believe that the news situation should be followed meticulously. Initial speculative positions make perfect sense.

    Investment in bio-pharma shares is accompanied by high fluctuations. The prices move very violently, according to the information on studies and approvals. Bayer and CureVac are in special situations, but a quick turnaround is always possible. On the other hand, Cardiol Therapeutics is at the beginning of the development curve and is researching an area with blockbuster potential!

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author

    Related comments:

    Commented by Juliane Zielonka on April 12th, 2024 | 07:00 CEST

    AI in healthcare with Evotec, Defence Therapeutics, Bayer: Revolutionary advances and medical breakthroughs

    • Biotechnology
    • Pharma
    • AI

    Artificial intelligence (AI) is gaining momentum in the healthcare sector. AI-based systems can use medical databases to save valuable time in research, enabling companies like Defence Therapeutics to go to market faster than others. In oncology research, the Canadian company has just achieved a breakthrough that gives hope to many cancer patients. AI-assisted diagnoses allow diseases to be detected earlier and treated more effectively, leading to improved quality of life for patients. Precision medicine in strong partnership networks is Evotec's focus. The share is particularly popular with hedge fund managers. Analyzing medical images and data in real-time and detecting even the smallest deviations or anomalies is the top priority for Bayer AG in collaboration with Google Cloud. Which companies are convincing investors the most?


    Commented by Fabian Lorenz on April 10th, 2024 | 07:00 CEST

    BASF and Cardiol Therapeutics recommended to buy! TUI share with momentum!

    • Biotechnology
    • Cancer
    • travel
    • chemicals

    BASF shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the share did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see little potential for further price increases. The situation is different for the biotech company Cardiol Therapeutics. The analysts at Canaccord believe that the shares of the specialist in cardiovascular diseases could perform by around 200%. Financing is secured until 2026, and important study data is due in the current quarter. The TUI share has been on a roll for several months now. Will the share continue to rise with the increase in temperatures? Management is certainly optimistic about the future.


    Commented by André Will-Laudien on April 10th, 2024 | 06:45 CEST

    Attention: Biotech takeovers, after MorphoSys, now Bayer, Vidac Pharma, BioNTech and Pfizer are on the radar

    • Pharma
    • Biotechnology
    • Innovations

    Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys recently got hearts beating again, as Novartis put a whopping EUR 2.7 billion on the table for the cancer specialist from Munich. Only months before, MorphoSys had been traded on the stock exchange at just EUR 700 million. The special market situation in this case was also characterized by the high short ratio, which led to an exorbitant rise in the share price of almost 400% in the final phase. Speculative investors are now keeping a wary eye on potential takeover candidates as the sector is once again attracting considerable attention. We are taking a closer look and searching for the next pearl.